Gilead Sciences Inc (GILD)

88.55
2.00 2.31
NASDAQ : Health Care
Prev Close 86.55
Open 86.57
Day Low/High 86.28 / 88.85
52 Wk Low/High 77.92 / 120.37
Volume 15.35M
Avg Volume 9.48M
Exchange NASDAQ
Shares Outstanding 1.33B
Market Cap 116.19B
EPS 12.40
P/E Ratio 7.27
Div & Yield 1.88 (2.20%)

Latest News

Gilead Sciences Announces Third Quarter 2016 Dividend

Gilead Sciences Announces Third Quarter 2016 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2016 Financial Results

Gilead Sciences Announces Second Quarter 2016 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2016.

Is Timeframe on Your Side?

Is Timeframe on Your Side?

Earnings reports will test the timeframe mettle for some investors and traders.

Gilead Readying for Earnings Report

Gilead Readying for Earnings Report

The biopharmaceutical giant is getting ready to report its second-quarter results, which are set to be released after Monday's close.

Morning Movers: YHOO, VZ, DHR, GILD

Morning Movers: YHOO, VZ, DHR, GILD

Verizon won the competitive bidding process for Yahoo and will pay the company $4.8 billion for its internet properties.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

Verizon strikes a $4.8 billion deal to acquire Yahoo!'s core operations, while Tesla and SolarCity are closer to a merger agreement.

What to Watch This Week: Apple, Facebook, Alphabet Report Earnings; Federal Reserve Meeting

What to Watch This Week: Apple, Facebook, Alphabet Report Earnings; Federal Reserve Meeting

A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?

Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report

Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report

Gilead Sciences (GILD) is scheduled to report earnings on Monday, July 25 after the market close.

European CHMP Adopts Positive Opinion On Gilead's Type II Variation Application For Truvada® For Reducing The Risk Of Sexually Acquired HIV

European CHMP Adopts Positive Opinion On Gilead's Type II Variation Application For Truvada® For Reducing The Risk Of Sexually Acquired HIV

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the...

Gilead's Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective In Two Phase 3b Studies

Gilead's Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective In Two Phase 3b Studies

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3b switch studies evaluating Odefsey ® (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met...

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Gilead Sciences To Release Second Quarter 2016 Financial Results On Monday, July 25, 2016

Gilead Sciences To Release Second Quarter 2016 Financial Results On Monday, July 25, 2016

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes.

Don’t Give Up On Gilead Sciences

Don’t Give Up On Gilead Sciences

The biotech juggernaut still has a lot going for it, especially at these levels.

Things Are too Giddy for My Taste

But without negative divergences of consequence it’s hard to be bearish,

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Jim Cramer's 'Mad Money' Recap: Stock Prices Just Getting Started

Jim Cramer's 'Mad Money' Recap: Stock Prices Just Getting Started

Listen to what the companies are actually telling you. Then assess what that might mean for the future, Cramer says.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

The GOP's Tax Plan Is Great for Corporate America

The GOP's Tax Plan Is Great for Corporate America

The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

An earlier rally lasted through the afternoon, pushing the S&P 500 and Dow Jones Industrial Average to close at fresh records.

Gilead (GILD) Stock Advancing on Credit Suisse Note

Gilead (GILD) Stock Advancing on Credit Suisse Note

Shares of Gilead (GILD) are up after Credit Suisse released a bullish note on the company.

Gilead's Major Trend Is Still Down

Gilead's Major Trend Is Still Down

Each bounce in the stock has been followed by a move to lower lows.

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Jim Cramer's 'Mad Money' Recap: I'll Tell You Why This Market Is Jumping

Jim Cramer's 'Mad Money' Recap: I'll Tell You Why This Market Is Jumping

Cramer says there are several reasons why the market has risen since the Brexit vote.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.